Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment

Clinical Liver Disease

Volumn 3, Issue 3, 2014, Pages 65-68

  Lin, M Valerie ^a   Chung, Raymond ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABT 267; ABT 450; ANTIVIRUS AGENT; ASUNAPREVIR; BLOCKING AGENT; BOCEPREVIR; CYCLOPHILIN INHIBITOR; CYCLOSPORIN; DACLASTAVIR; EMTRICITABINE; LAMIVUDINE; LEDIPASVIR; MARAVIROC; MICRORNA ANTAGONIST; MK 5172; MK 8742; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; TELAPREVIR; TENOFOVIR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADD ON THERAPY; ANEMIA; ANTIVIRAL ACTIVITY; ARTICLE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LIVER CIRRHOSIS; LIVER FIBROSIS; MIXED INFECTION; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT INDICATION; VIRUS INHIBITION;

EID: 84897441196     PISSN: None     EISSN: 20462484     Source Type: Journal    
DOI: 10.1002/cld.332     Document Type: Article

References (13)

1. Fusco DN, Chung RT. Novel therapies for hepatitis C: insights from the structure of the virus. Annu Rev Med 2012;63:373-387.
2. Murakami E, Tolstykh T, Bao H, Niu C, Steuer HM, Bao D, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 2010;285:34337-34347.
3. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
4. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-1877.
5. Zeuzem S DG, Salupere R, et al. Sofosbuvir+ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, November 1-5, 2013. Abstract 1085.
6. Sulkowski MS R-TM, Lalezari JP, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, November 1-5, 2013. Abstract 212.
7. Lin TI, Lenz O, Fanning G, Verbinnen T, Delouvroy F, Scholliers A, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009;53:1377-1385.
8. Jacobson IM. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment-naive patients; results from QUEST-1, a phase III trial. Digestive Disease Week, Orlando, FL, May 18-21, 2013. Abstract 1674582.
9. Poordad F. Simeprevir with peginterferon-a2a or -a2b and ribavirin in treatment-naive HCV genotype 1 patients: QUEST-2, a randomized phase III trial. Digestive Disease Week, Orlando, FL, May 18-21, 2013. Abstract 070313.
10. Lawitz E. Simeprevir with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from PROMISE, a phase III trial. Digestive Disease Week, Orlando, FL, May 18-21, 2013. Abstract 869b.
11. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014;146:430-441.
12. Lawitz E, Poordad F, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515-523.
13. Jacobson IM, Ghalib RH, Rodriguez-Torres M, Younossi ZM, Corregidor A, Sulkowski MS, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: the COSMOS study. Hepatology 2013;58:1379A.